argenex (NASDAQ:ARGX) Stock Gets Price Target Cut from Guggenheim

argenex (NASDAQ:ARGX) had its target price trimmed by Guggenheim from $1,185.00 to $1,120.00 in a research note published on Friday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Several other research analysts have also recently issued reports on ARGX. Citigroup lifted their target price on argenex from $1,152.00 to $1,182.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. Wells Fargo & Company reduced their price objective on shares of argenex from $1,356.00 to $1,336.00 and set an “overweight” rating for the company in a research report on Friday. Truist Financial lifted their target price on shares of argenex from $1,030.00 to $1,095.00 and gave the stock a “buy” rating in a research report on Tuesday, August 18th. Sanford C. Bernstein restated a “buy” rating on shares of argenex in a research note on Thursday, October 8th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of argenex in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, argenex has a consensus rating of “Moderate Buy” and an average target price of $1,142.37.

argenex Stock Performance

Shares of NASDAQ ARGX opened at $873.71 on Friday. The stock has a market cap of $54.95 billion, a price-to-earnings ratio of 30.49, a PEG ratio of 0.89 and a beta of 0.44. argenex has a fifty-two week low of $661.85 and a fifty-two week high of $1,072.75. The firm’s 50-day simple moving average is $956.62 and its 200 day simple moving average is $886.34.

argenex (NASDAQ:ARGX) last issued its quarterly earnings data on Friday, October 23rd. The company reported $7.80 EPS for the quarter, topping analysts’ consensus estimates of $7.44 by $0.36. The firm had revenue of $1.75 billion during the quarter. argenex had a return on equity of 47.70% and a net margin of 31.66%. On average, sell-side analysts predict that argenex will post 25.79 EPS for the current year.

Institutional Investors Weigh In On argenex

A number of hedge funds have recently made changes to their positions in ARGX. Sigma Planning Corp bought a new stake in argenex in the 3rd quarter valued at about $1,027,000. Signaturefd LLC lifted its holdings in argenex by 2.6% during the third quarter. Signaturefd LLC now owns 2,129 shares of the company’s stock valued at $2,041,000 after purchasing an additional 54 shares during the last quarter. BG Investment Services LLC bought a new position in argenex during the third quarter worth about $1,397,000. Sowell Financial Services LLC boosted its position in argenex by 25.8% during the third quarter. Sowell Financial Services LLC now owns 459 shares of the company’s stock worth $440,000 after purchasing an additional 94 shares during the period. Finally, Guardian Partners Inc. purchased a new position in shares of argenex in the third quarter worth about $863,000. 60.32% of the stock is currently owned by institutional investors.

Trending Headlines about argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Strong quarterly results: argenx reported $7.80 in EPS, exceeding the $7.44 consensus estimate, while revenue reached $1.75 billion. Product net sales grew 54% year over year to $1.7 billion, and operating profit was $486 million. argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Bullish analyst support: Morgan Stanley raised its price target from $1,140 to $1,190 and maintained an “overweight” rating. Wells Fargo also maintained “overweight” despite trimming its target from $1,356 to $1,336. Jefferies called the post-news setup a potentially attractive entry point. Morgan Stanley rating
• Neutral Sentiment: Targets remain above the market price, but revisions are mixed: Guggenheim lowered its target from $1,185 to $1,120 while keeping a “buy” rating. Robert W. Baird raised its target from $823 to $861 but retained a “neutral” rating, and RBC reportedly cut its target. These changes suggest continued confidence in long-term value but more cautious near-term expectations. Guggenheim rating
• Negative Sentiment: Clinical-development setback is overshadowing the earnings beat: Reports highlighted a surprise testing setback for argenx’s core drug, raising concerns about future growth, product expansion and execution. That issue appears to be driving the weaker investor reaction despite the company’s strong sales and profitability. argenx testing setback

About argenex

argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.